Article
Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations.
Journal of cancer research and therapeutics - 1 Jan 2000
Yanwei Zhang, Bo Jin, Yuqing Lou, Rong Li, Xueyan Zhang, Song Hu, Baohui Han
Abstract excerpt
OBJECTIVES: Not all the patients harboring epidermal growth factor receptor (EGFR) mutations have a clinical response after the treatment of EGFR-tyrosine kinase inhibitor (TKI). The purpose of the present study was to find whether the baseline carcinoembryonic antigen (CEA) levels were associated with the efficacy of EGFR-TKI in patients harboring EGFR mutations. MATERIALS AND METHODS: Clinical features, serum...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
